地尔硫卓缓解冠脉痉挛的临床疗效

目的：探讨地尔硫卓治疗冠脉痉挛的临床疗效及安全性。方法：选择我院的100例冠脉痉挛患者，按照抽签法随机均分为：常规治疗组（50例，予以调脂、扩冠等常规治疗）；地尔硫卓组（50例，在常规治疗基础上泵入地尔硫卓），比较两组临床、心电图疗效及治疗前后一氧化氮（NO），内皮素-1（ET-1）水平等的变化和安全性。结果：（1）与常规治疗组比较，地尔硫卓组临床治疗总有效率（60.00％比94.00％）、心电图总疗效（62.00％比92.00％）显著提高（P均＜0.01）；（2）两组治疗后心电图各项指标、心率、血压均较治疗前明显改善，且地尔硫卓组较常规治疗组改善更显著（P均＜0.05）；（3）地尔硫卓组治疗后血脂水平较治疗前及常规组治疗后有明显改善（P均＜0.05）；（4）与治疗前及常规治疗组比较，治疗后地尔硫卓组 NO 水平[（95.17±19.99）μmol/L、（95.17±21.22）μmol/L比（106.71±22.38）μmol/L]显著升高、ET-1水平[（64.09±16.29）ng/L、（59.98±14.28）ng/L比（44.91±6.38）ng/L]显著降低（P均＜0.05）；（6）两组治疗过程中，均未出现任何不良反应。结论：在常规药物治疗的基础上加用地尔硫卓治疗冠脉痉挛，疗效显著，安全性高，值得推广。

Clinical therapeutic effect of diltiazem treating coronary artery spasm

Objective：To explore clinical therapeutic effect and safety of diltiazem treating coronary artery spasm. Methods：A total of 100 patients with coronary artery spasm were selected in our hospital.According to number table method,they were randomly and equally divided into routine treatment group （n=50,received,lipid regulation and expanding coronory artery etc.）and diltiazem group （n=50,received diltiazem pumping based on routine treatment）.Clinical and ECG therapeutic effect,changes of blood lipids,nitric oxide （NO）and endothelin-1 （ET-1） levels before and after treatment and safety were compared between two groups.Results：（1 ）Compared with routine treatment group,there were significant increase in total effective rates of clinical effect （60.00% vs.94.00%） and ECG （62.00% vs.92.00%）in diltiazem group,P〈0.01 both;（2）Compared with before treatment,there were significant improvements in all ECG indexes,heart rate and blood pressure in two groups after treatment,and those of diltiazem group were significantly better than those of routine treatment group （P〈0.05 all）;（3）Compared with before treatment and routine treatment group,there were significant improvements in blood lipid levels in diltiazem group after treatment （P〈0.05 all）;（4）Compared with before treatment and routine treatment group,there was significant rise in NO level [（95.17±19.99）μmol/L,（95.17±21.22）μmol/L vs.（106.71± 22.38）μmol/L]and significant reduction in ET-1 level [（64.09±16.29）ng/L,（59.98±14.28）ng/L vs.（44.91± 6.38）ng/L]in diltiazem group after treatment （P〈0.05 all）;（6）During treatment,there were no adverse reaction in both groups.Conclusion：Diltiazem based on routine medication possess significant therapeutic effect and high safety for treating coronary artery spasm,which is worth extension in clinic.